Identification of genetic markers for everolimus-resistance in patients with pancreatic neuroendocrine tumors University of Antwerp
Center for Oncological Research (CORE), Human molecular genetics, Molecular Imaging, Pathology, Radiotherapy & Oncology (MIPRO)
Everolimus is a targeted therapy commonly used for patients with advanced pancreatic neuroendocrine tumors (PNETs). Unfortunately, after a while patients develop resistance, seen as progression on medical images. Earlier detection of resistance allows a quicker change to more effective therapies, results in better patient outcome, spares patients from ineffective treatment and reduces costs for society. Building on cell line data, fusion genes ...